Cervical incompetence

Summary

Cervical incompetence (MONDO:0005698) is a disease and 9 clinical trials. Top therapeutic interventions include bupivacaine and chloroprocaine. A subtype of cervix disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical incompetence
Mondo ID	MONDO:0005698
EFO	EFO:0007202
MeSH	D002581
DOID	DOID:9681
SNOMED CT	17382005
UMLS	C0007871
MedGen	2972
Is cancer (heuristic)	no

Disease family

This is a subtype of cervix disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › uterine disorder › cervix disorder › cervical incompetence

Related subtypes (8): cervical polyp, hypertrophic elongation of cervix, cervicitis, cervix endometriosis, uterine cervix leukoplakia, cervical metaplasia, cervix erosion, uterine cervix neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE1	2
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03305575	PHASE4	COMPLETED	Intrathecal Chloroprocaine vs. Bupivacaine for Cervical Cerclage
NCT03077633	PHASE2/PHASE3	WITHDRAWN	Cerclage for Twins With Short Cervix
NCT03992534	PHASE1	UNKNOWN	The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth
NCT05512052	PHASE1	UNKNOWN	Preventing Preterm Birth With a Negative Pressure Cervical Cup: a Feasibility Study
NCT03311867	Not specified	COMPLETED	Prolene Versus Ethibond for Cervical Cerclage
NCT03636048	Not specified	TERMINATED	Comparison of Anesthesia Type in Patients Undergoing Transabdominal Cervico Isthmic Cerclage (TCIC)
NCT03837288	Not specified	UNKNOWN	Cervical Cerclage for Singleton Pregnant on Vaginal Progesterone With Progressive Cervical Length Shortening
NCT05268640	Not specified	COMPLETED	Cervical Occlusion Double-level Stitch Application
NCT06443112	Not specified	COMPLETED	Pregnancy Outcomes According to Cervical Cerclage Indications and Factors Affecting Pregnancy Duration and Outcomes

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BUPIVACAINE	4	2
CHLOROPROCAINE	4	1